Biomarkers in Gastrointestinal Cancer: Expert Perspectives and Guidance for Individualized Treatment

Join us for this 1.5-hour CME-certified symposium held in conjunction with the 2022 ASCO Annual Meeting featuring expert perspectives on molecular testing, predictive biomarkers, and targeted therapy for patients with GI malignancies. Bring your questions for the live Q&A session with the expert panel faculty at the end of the session.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Not an official event of the 2022 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer® the ASCO Foundation.


  • Histology-Agnostic Biomarkers in GI Malignancies
  • Biomarker-Driven Treatment of Advanced Colorectal Cancer
  • Biomarker-Driven Treatment of Pancreatic and Hepatobiliary Cancer
  • Biomarker-Driven Treatment: Gastric, Esophageal, and Gastroesophageal Junction Cancers
  • Live Audience Question and Answer Session


Date / Time
Event Details


Program Director
John L. Marshall, MD

Chief, Division of Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

Michael Pishvaian, MD, PhD

Associate Professor
Department of Gastrointestinal Medical Oncology
Co-director for Clinical Research
Ahmed Bin Zayed Al Nahyan Center for Pancreatic Cancer Research
The University of Texas MD Anderson Cancer Center
Houston, Texas

Manish Shah, MD

Bartlett Family Professor of Gastrointestinal Oncology
Solid Tumor Services
Director, Gastrointestinal Oncology Program
Weill Cornell Medical College
 New York, New York

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in biomarker testing to guide selection of individualized treatments for patients with gastrointestinal malignancies.

Target Audience
This educational program is intended for medical oncologists and other healthcare professionals who treat patients with gastrointestinal malignancies.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Apply the available data and expert recommendations for molecular profiling in GI malignancies to guide treatment selection
  • Plan individualized therapeutic strategies for patients with GI malignancies based on predictive biomarker assessment
  • Counsel patients on tumor molecular profile and how this information will guide therapy decisions to optimize outcomes and quality of life
  • Appraise ongoing clinical trials for novel biomarker-driven treatment strategies in GI malignancies for patient counsel and potential enrollment


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.